Investment
Features
FeesSafety
Academy
More
Pluang+

Compare T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) vs Revvity Inc (RVTY) Price & Performance

T-Rex 2X Inverse MSTR Daily Target ETFTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

T-Rex 2X Inverse MSTR Daily Target ETF vs Revvity Inc — how do they compare? T-Rex 2X Inverse MSTR Daily Target ETF trades at $4.21, while Revvity Inc trades at $124.14 (market cap $14.18B). The key difference: Revvity Inc pays a 0.22% dividend while T-Rex 2X Inverse MSTR Daily Target ETF pays none, and Revvity Inc is trading nearer its 52-week high, T-Rex 2X Inverse MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.

MSTZRVTY
Sector
Leveraged / InverseTechnology
52-Week High
$27.92$130.94
52-Week Low
$3.63$82.26
Market Cap
$14.18B
Enterprise Value
$16.50B
Dividend Yield
0.22%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

T-Rex 2X Inverse MSTR Daily Target ETF

MSTZ trades at $4.04, up 8.46% in the last 24 hours, but technical indicators signal a bearish trend with moving averages and ADX strongly bearish. The stock lacks disclosed financial ratios, suggesting limited fundamental data availability. Recent news highlights ETFs betting against related stocks, indicating negative sentiment in its sector.

The outlook is cautious due to bearish technicals and sparse fundamentals. Risks include market volatility and competitive pressures, with no clear catalysts for upside. Investors should seek updated financial filings for a clearer assessment.

Revvity Inc

RVTY trades at $127.08, down 2.41% on the day, with a bullish technical signal from moving averages and strong support at $126. The company reported Q2 2026 EPS of $1.41, beating estimates, and raised its full-year outlook, driven by diagnostics strength and improved cash flow. Recent news includes the acquisition of Human Cell Design and the launch of the SuperFlex prenatal screening system.

Outlook is positive with 52% analyst buy ratings and a $135.25 consensus price target, implying ~6% upside. Risks include a premium valuation (P/E 61.1) and execution of growth initiatives. Strong institutional interest, such as Bank of New York Mellon's $78.77 million investment, supports confidence in the stock's trajectory.

Returns comparison

Trailing returns across standard periods

About T-Rex 2X Inverse MSTR Daily Target ETF

MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.

Read more on MSTZ

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY